CVE:COT Cotinga Pharmaceuticals Inc. (COT.V) (COT) Stock Price, News & Analysis C$0.04 -0.03 (-41.67%) As of 10/14/2020 Add Compare Share Share Stock Analysis Stock Analysis About Cotinga Pharmaceuticals Inc. (COT.V) Stock (CVE:COT) Get COT alerts:Sign Up Key Stats Today's RangeC$0.04▼C$0.0450-Day RangeC$0.04▼C$0.0452-Week RangeC$0.02▼C$0.12Volume1,000 shsAverage Volume20,281 shsMarket CapitalizationC$769.51 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Cotinga Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. The company's lead compound is COTI-2, an oral small molecule targeting p53 a tumor suppressor gene. It also develops COTI-219, an oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS functions. Cotinga Pharmaceuticals Inc. has a research collaboration with St. Vincent's University Hospital to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer. The company was formerly known as Critical Outcome Technologies Inc. and changed its name to Cotinga Pharmaceuticals Inc. in January 2018. Cotinga Pharmaceuticals Inc. is based in Toronto, Canada. Read More Receive COT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cotinga Pharmaceuticals Inc. (COT.V) and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. COT Stock News HeadlinesV BREAKING NEWS: Visa Inc. Investors that Suffered Losses are Encouraged to Contact Rosen Law about Ongoing Investigation into the Company - VNovember 11, 2024 | markets.businessinsider.comKalVista Pharmaceuticals Inc.May 1, 2024 | wsj.comI'm giving you a space stock today. Free.On December 8th, $600 billion in frozen SpaceX stock comes loose. Dylan Jovine says one simple purchase in any regular brokerage account gives investors exposure to SpaceX and 66 of its neighbors, without an IPO allocation. He is also naming two space stocks he would consider dumping before December, plus a $14 stock that Elon has personally put his name on.October 16 at 1:00 AM | Behind the Markets (Ad)Lexicon Pharmaceuticals Inc.February 14, 2024 | wsj.comAcumen Pharmaceuticals Inc ABOSNovember 5, 2023 | morningstar.comMSXTP 60 Degrees Pharmaceuticals, Inc.July 21, 2023 | seekingalpha.com8-K: ENANTA PHARMACEUTICALS INCApril 28, 2023 | marketwatch.comIronwood Pharmaceuticals, Inc. 2022 Q4 - Results - Earnings Call PresentationFebruary 18, 2023 | seekingalpha.comSee More Headlines COT Stock Analysis - Frequently Asked Questions How have COT shares performed this year? Cotinga Pharmaceuticals Inc. (COT.V)'s stock was trading at C$0.04 at the start of the year. Since then, COT stock has increased by 0.0% and is now trading at C$0.04. Industry, Sector and Symbol Stock ExchangeCVE SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolCVE:COT CIKN/A Webcotingapharma.com Phone+1-519-8585157FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio0.05 Quick Ratio0.01 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowC$0.00 per share Price / Cash Flow17.50 Book ValueC($0.18) per share Price / Book-0.20Miscellaneous Outstanding Shares21,986,000Free FloatN/AMarket CapC$769.51 thousand OptionableNot Optionable BetaN/A 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (CVE:COT) was last updated on 10/14/2020 by MarketBeat.com Staff. From Our PartnersElon Musk’s 4th Wealth Window Set to Open by October 30Jeff Brown, the analyst who flagged Bitcoin, Tesla, and Nvidia early, is tracking Elon Musk's next move. He po...Brownstone Research | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...Investors Alley | SponsoredTrump’s Plan To Cheat HistoryChina has slashed its U.S. Treasury holdings by more than 45% from their peak, while building gold vaults and ...Porter & Company | SponsoredSpaceX minted 4400 millionaires in a single daySpaceX minted 4,400 millionaires in a single day, and Tesla has turned more than 5,000 employees into milliona...Behind the Markets | SponsoredTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredUndiscovered Sub-$1 Gold-Silver Royalty Stock Takes FlightA small-cap gold and silver royalty company is generating record revenue from producing mines, yet shares stil...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cotinga Pharmaceuticals Inc. (COT.V) Please log in to your account or sign up in order to add this asset to your watchlist. Share Cotinga Pharmaceuticals Inc. (COT.V) With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.